Matches in SemOpenAlex for { <https://semopenalex.org/work/W2273669289> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2273669289 endingPage "32" @default.
- W2273669289 startingPage "26" @default.
- W2273669289 abstract "Coronary artery disease (CAD) is a highly prevalent condition with life-threatening consequences. The most common presenting symptom of CAD is the chest pain associated with angina.Angina occurs when myocardial perfusion is inadequate to meet oxygen demand. An increased heart rate (HR) plays a vital role in CAD, not only as a trigger of most ischaemic events, but also as an important predictor of cardiovascular morbidity and mortality. Therefore HR reduction plays a central role in the management of patients with angina pectoris.Current pharmacological management recommended by guidelines for the treatment of chronic stable angina includes β-blockers, calcium-channel blockers and organic nitrates. However, their use has limitations due to tolerance to the therapeutic effect, relative contraindications or side effects. In view of these limitations, a new pharmacological target was sought. This led to the launch of ivabradine, a selective and specific 1f inhibitor, which acts on the ionic currents for the regulation of pacemaker activity in the sinoatrial (SA) node cells. Ivabradine slows the slope of diastolic depolarisation of the action potential in the SA node cells and decreases HR at rest and during exercise.Several clinical trials demonstrated dose-dependent anti-ischaemic and anti-anginal effects of ivabradine. There was no pharmacological tolerance or rebound phenomena upon withdrawal of ivabradine. Ivabradine was also found to have a good safety and tolerability profile with the main side effect being dose-related visual symptoms that were transient and mild in nature. Bradycardia may however be a problem with combination therapy.Ivabradine is expected to give symptomatic relief to patients with chronic stable angina, especially those who have contra-indications or intolerance to current pharmacological options or who are insufficiently controlled on monotherapy. Long-term cardiovascular mortality benefits however need to be established." @default.
- W2273669289 created "2016-06-24" @default.
- W2273669289 creator A5047723422 @default.
- W2273669289 creator A5053891542 @default.
- W2273669289 date "2009-05-01" @default.
- W2273669289 modified "2023-09-26" @default.
- W2273669289 title "Ivabradine - the first 1f inhibitor for the treatment of chronic stable angina : medifile" @default.
- W2273669289 hasPublicationYear "2009" @default.
- W2273669289 type Work @default.
- W2273669289 sameAs 2273669289 @default.
- W2273669289 citedByCount "0" @default.
- W2273669289 crossrefType "journal-article" @default.
- W2273669289 hasAuthorship W2273669289A5047723422 @default.
- W2273669289 hasAuthorship W2273669289A5053891542 @default.
- W2273669289 hasConcept C126322002 @default.
- W2273669289 hasConcept C164705383 @default.
- W2273669289 hasConcept C197934379 @default.
- W2273669289 hasConcept C2777495988 @default.
- W2273669289 hasConcept C2777953023 @default.
- W2273669289 hasConcept C2778213512 @default.
- W2273669289 hasConcept C2778375690 @default.
- W2273669289 hasConcept C2778425758 @default.
- W2273669289 hasConcept C2778542873 @default.
- W2273669289 hasConcept C2779167562 @default.
- W2273669289 hasConcept C42219234 @default.
- W2273669289 hasConcept C500558357 @default.
- W2273669289 hasConcept C71924100 @default.
- W2273669289 hasConcept C84393581 @default.
- W2273669289 hasConceptScore W2273669289C126322002 @default.
- W2273669289 hasConceptScore W2273669289C164705383 @default.
- W2273669289 hasConceptScore W2273669289C197934379 @default.
- W2273669289 hasConceptScore W2273669289C2777495988 @default.
- W2273669289 hasConceptScore W2273669289C2777953023 @default.
- W2273669289 hasConceptScore W2273669289C2778213512 @default.
- W2273669289 hasConceptScore W2273669289C2778375690 @default.
- W2273669289 hasConceptScore W2273669289C2778425758 @default.
- W2273669289 hasConceptScore W2273669289C2778542873 @default.
- W2273669289 hasConceptScore W2273669289C2779167562 @default.
- W2273669289 hasConceptScore W2273669289C42219234 @default.
- W2273669289 hasConceptScore W2273669289C500558357 @default.
- W2273669289 hasConceptScore W2273669289C71924100 @default.
- W2273669289 hasConceptScore W2273669289C84393581 @default.
- W2273669289 hasIssue "4" @default.
- W2273669289 hasLocation W22736692891 @default.
- W2273669289 hasOpenAccess W2273669289 @default.
- W2273669289 hasPrimaryLocation W22736692891 @default.
- W2273669289 hasRelatedWork W1485113287 @default.
- W2273669289 hasRelatedWork W182841154 @default.
- W2273669289 hasRelatedWork W1964038018 @default.
- W2273669289 hasRelatedWork W1982585258 @default.
- W2273669289 hasRelatedWork W1987652251 @default.
- W2273669289 hasRelatedWork W1991276113 @default.
- W2273669289 hasRelatedWork W2013665486 @default.
- W2273669289 hasRelatedWork W2038962385 @default.
- W2273669289 hasRelatedWork W2094837984 @default.
- W2273669289 hasRelatedWork W2102846343 @default.
- W2273669289 hasRelatedWork W2104079246 @default.
- W2273669289 hasRelatedWork W2142707978 @default.
- W2273669289 hasRelatedWork W2152482983 @default.
- W2273669289 hasRelatedWork W2164569703 @default.
- W2273669289 hasRelatedWork W2234849782 @default.
- W2273669289 hasRelatedWork W2259989142 @default.
- W2273669289 hasRelatedWork W2481087274 @default.
- W2273669289 hasRelatedWork W2790843172 @default.
- W2273669289 hasRelatedWork W2183966884 @default.
- W2273669289 hasRelatedWork W3150970203 @default.
- W2273669289 hasVolume "76" @default.
- W2273669289 isParatext "false" @default.
- W2273669289 isRetracted "false" @default.
- W2273669289 magId "2273669289" @default.
- W2273669289 workType "article" @default.